Skip to content

Clinical Efficiency and Safety of the Longanoid Cream Formulation Versus Diclofenac gel in Symptomatic Treatment of Osteoarthritis of Knee

Clinical Efficiency and Safety of the Longanoid Cream Formulation Versus Diclofenac gel in Symptomatic Treatment of Osteoarthritis of Knee

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-11001762
Enrollment
Unknown
Registered
2011-12-02
Start date
2012-01-06
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Interventions

2:VAS of pain
3:VAS of pain

Sponsors

Agricultural Research Development Agency
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
25 Years to No maximum

Inclusion criteria

Inclusion criteria: Out-patients of either sex, age over 25, suffer ing from OA of knee (unilateral or bilateral) according to the criteria of the American College of Rheumatoloy as: knee pain and radiographic osteophytes and at least 1 of the following 3 items: age over 50 years, morning stiffness not more than 30 min in duration, or crepitus on motion. The symptoms must be present for more than 3 months. After stop using usual medications for 7 days, VAS of total pain must be > or = 200 and < or = 350. Participants must be capable of walking. All patients have to sign the written consent form to participate in the study.

Exclusion criteria

Exclusion criteria: Patients must not have the following diseases or conditions: an underlying inflammatory arthropathy, acute or chronic gouty arthritis, hyperuricemia > 9 mg/dl with or without history of gouty attack, expectation of surgery in the near future, recent injury in the area affected by OA of knee, active inflammation of OA of knee, significant knee joint effusion, intra-articular corticosteroid injections within the last 3 months, continuous use of the symptomatic slow-acting drugs for osteoarthritis (SYSDOA) [e.g., glucosamine sulphate, chondroitin sulphate, diacerein, and hyaluronic acid] less than 4 months or stop using these drugs less than 6 months, hypersensitivity to NSAIDs, concomitant skin disease at the application site, pregnancy and lactation.

Design outcomes

Primary

MeasureTime frame
Number of Responsder;

Secondary

MeasureTime frame
VAS of pain;VAS of stiffness;Lequense's functional index;

Countries

Thailand

Contacts

Public ContactAssoc. Prof. Dr. Supanimit Teekachunhatean
steekach@med.cmu.ac.th+66 0 53945353

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026